Citations 1
Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program
Cohen, Stuart H. , Allyn, Paul , Rathe, Jennifer , Nanayakkara, Deepa , Hutfles, Gerald, Vijayan, Tara , Smith, Ethan A , Saling, Christopher , Ilges, Dan , Schlamm, Haran T., Thompson, George R. , Rathe, Jennifer , Hutfles, Gerald , Vijayan, Tara , Smith, Ethan A , Ilges, Dan , Thompson, George R , Allyn, Paul R , Chow, Felicia C.
Clinical Infectious Diseases | April 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract Coccidioidomycosis is an invasive fungal infection that can disseminate and cause severe disease. Fosmanogepix (“gepix”), a first-in-class antifungal available via expanded access (NCT06433128), was successful in 8/11 patients (meningitis, 6/8 [75%]; nonmeningeal dissemination, 2/3 [66%]) and was well tolerated for a median treatment duration of 208 days.